SEPTODONT, SOCIETE ANONYME – Trademark Portfolio
Entity Type: 03
SEPTODONT, SOCIETE ANONYME holds 36 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 27 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 3 Nice Classification classes. Currently, 7 trademarks are registered. Notable registered marks include ENDOMET, SEPTODONT, SEPTOCAINE, and SAFETY PLUS. The owner is based in PARIS.
29 RUE DES PETITES ECURIES
PARIS , FR
Showing of trademarks Trademarks
Trademark Classifications
SEPTODONT, SOCIETE ANONYME's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Frequently Asked Questions
How many trademarks does SEPTODONT, SOCIETE ANONYME have?
SEPTODONT, SOCIETE ANONYME has 36 U.S. trademarks filed with the USPTO. Of these, 7 registered, 18 abandoned, 11 cancelled.
What trademark classes does SEPTODONT, SOCIETE ANONYME file in?
SEPTODONT, SOCIETE ANONYME files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 3 (Cosmetics & Cleaning), Class 10 (Medical Apparatus). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are SEPTODONT, SOCIETE ANONYME's most well-known trademarks?
SEPTODONT, SOCIETE ANONYME's registered trademark portfolio includes well-known marks such as ENDOMET, SEPTODONT, SEPTOCAINE, and SAFETY PLUS. These are among 7 currently registered trademarks in the portfolio.
What is SEPTODONT, SOCIETE ANONYME's trademark registration success rate?
SEPTODONT, SOCIETE ANONYME has a 19% trademark registration rate, with 7 out of 36 resolved applications resulting in successful registration. Currently, 0 applications are pending review.